Have a Nephrology Question? There Might Be A #Tweetorial For That!
Conferences, Courses, & Grants
FOAMed
Interventional Nephrology Series
Focus on Point-of-Care Ultrasound in Nephrology (POCUN) Series
Landmark Nephrology Series
Kidney Biopsy of the Month Series
Urine Sediment of the Month Series
The Skeleton Key Group: Electrolyte Cases
Landmark Nephrology: Use of Rituximab in Lupus Nephritis
Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystem involvement and no cure. Among patients with SLE, roughly 50% develop lupus nephritis and are at risk of developing lupus nephritis-related end-stage kidney disease (ESKD). Current therapies for…
Landmark Trials in Anemia & Kidney Disease
As nephrologists, we remember the not so distant past when there were few options available to help patients battle the debilitating effects of anemia of chronic kidney disease. Fortunately, advances over the past two decades have led to…
Landmark Trials in Membranous Nephropathy
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in the Caucasian adult population with an estimated incidence of 8–10 cases per 1 million and commonly seen in males above the age of 40. It is…
Landmark Nephrology: Renal Replacement Therapy (RRT) Timing in Critically Ill Patients
Currently, the timing of initiation of renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) remains a challenge. T Despite several randomized controlled trials (RCTs) comparing early versus late initiation strategies of RRT, the…
Landmark Trials of Belatacept in Kidney Transplantation
The last few decades have been revolutionary in terms of improving end stage kidney disease (ESKD) care with respect to increasing the number of transplant recipients as well as upping the immunosuppression game. The use of calcineurin inhibitors…
Landmark Trials in Peritoneal Dialysis Adequacy: A 3-Minute Read
Peritoneal dialysis (PD) treatment began much earlier than hemodialysis but was not successful due to the many complications associated with it and the difficulties with access to the peritoneal cavity. It was in 1946 that Dr. Fine and…
Landmark Nephrology Highlights a Common Clinical Conundrum: Steroids for IgA Nephropathy
In an ideal world, patients would present to our clinic with straightforward conditions, allowing us to confidently treat the patient with effective medications which will likely have much more benefit than harm. However, we also commonly encounter patients…
Landmark Trials in Renal Artery Stenosis
Renal artery stenosis (RAS) can lead to a reduction in kidney blood flow with resultant ischemia of the affected kidney. The consequences of this reduction are a decline in estimated glomerular filtration rate (eGFR) and activation of the…
Landmark Trials in ANCA-Associated Vasculitis: Past, Present and To Be Cont’d…
Anti-neutrophil cytoplasm antibody (ANCA) was first described in 1982 in a case of segmental necrotizing glomerulonephritis (Fig. 1). The first international ANCA workshop in 1989 delineated a standard immunofluorescence technique to test for ANCA in kidney biopsy specimen….
Landmark Trials in ADPKD: Close, But No Cigar
Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease, affecting 1/400 to 1/1000 live births and is the fourth leading cause of end-stage kidney disease in adults. Both types of ADPKD (1 and 2) typically have…
